News | September 02, 2025
Revvity establishes In Vivo Imaging Center of Excellence in North Carolina
Facility designed to advance the next generation of imaging systems
Facility designed to advance the next generation of imaging systems
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
Subscribe To Our Newsletter & Stay Updated
